恒指考验26,200获支持倒升 药明生物及安踏续升2%-5.6%再破顶
英国出现传播力更强新冠病毒变种,引发市场恐慌,但美国国会就新一轮抗疫刺激经济方案达共识,加上联储局批准大型银行派发股息限制及明年首季恢复回购股份,道指昨晚在银行股重现买盘及部分科技股反弹支持收复曾挫423点所有失地逆市倒升0.1%重越30,200关。亚太区股市今天除新西兰回升1.4%及港股反覆回稳外,全部受压。
恒指承过去两连跌势,今早低开45点或0.2%报26,260,最低见26,204获承接,掉头高见26,365,现造26,321,倒升14点,成交额504亿元。
安踏(02020.HK)承昨天扭两连跌重越108元势,今早股价曾一举升破20天与10天线(108.9元及109.6元)及11月19日盘中所创纪录高位114.3元,最高见114.5元,现造114元,续升5.6%,为最强蓝筹,成交435万股,涉资近4.78亿元。安踏公布,公司持股52.7%合营AS Holding,拟以总代价4.2亿美元悉售旗下器械健身附属Precor Incorporated,预计合营出售事项将获利约2,000万美元。
药明生物(02269.HK)连续第二天反覆创纪录高,高低见94元/90.45元,现造92.5元,续升2%,公司宣布收购拜耳德国生物药原液制造工厂。此外,苹果昨晚反覆升逾1%,舜宇(02382.HK)扭两连跌重越10天线,最高见160.8元,现造159.4元,回升3.7%。小米(01810.HK)续升2.4%报30元,主席雷军称即将於下周一(28日)发布新手机「小米11」,并指是高端旗舰的再次突破。
相反,受困於英国疫情急剧恶化的长和(00001.HK)、长实集团(01113.HK)、万洲(00288.HK)、濠赌股银娱(00027.HK)及金沙(01928.HK)跌逾2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.